Galectins in Innate Immunity: Dual Functions of Host Soluble Beta-galactoside-binding Lectins As Damage-associated Molecular Patterns (DAMPs) and As Receptors for Pathogen-associated Molecular Patterns (PAMPs)
Overview
General Surgery
Affiliations
The glycocalyx is a glycan layer found on the surfaces of host cells as well as microorganisms and enveloped virus. Its thickness may easily exceed 50 nm. The glycocalyx does not only serve as a physical protective barrier but also contains various structurally different glycans, which provide cell- or microorganism-specific 'glycoinformation'. This information is decoded by host glycan-binding proteins, lectins. The roles of lectins in innate immunity are well established, as exemplified by collectins, dectin-1, and dendritic cell (DC)-specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN). These mammalian lectins are synthesized in the secretory pathway and presented on the cell surface to bind to specific glycan 'epitopes'. As they recognize non-self glycans presented by microorganisms, they can be considered as receptors for pathogen-associated molecular patterns (PAMPs), i.e. pattern recognition receptors (PRRs). One notable exception is the galectin family. Galectins are synthesized and stored in the cytoplasm, but upon infection-initiated tissue damage and/or following prolonged infection, cytosolic galectins are either passively released by dying cells or actively secreted by inflammatory activated cells through a non-classical pathway, the 'leaderless' secretory pathway. Once exported, galectins act as PRR, as well as immunomodulators (or cytokine-like modulators) in the innate response to some infectious diseases. As galectins are dominantly found in the lesions where pathogen-initiated tissue damage signals appear, this lectin family is also considered as potential damage-associated molecular pattern (DAMP) candidates that orchestrate innate immune responses alongside the PAMP system.
Tull S, Saviano A, Fatima A, Begum J, Mansour A, Marigliano N Biomed Pharmacother. 2025; 184:117902.
PMID: 39951917 PMC: 11870847. DOI: 10.1016/j.biopha.2025.117902.
Luz L, Ribeiro M, Teixeira S, de Souza G, Paschoalino M, Sousa D Front Cell Infect Microbiol. 2024; 14:1459810.
PMID: 39654979 PMC: 11625798. DOI: 10.3389/fcimb.2024.1459810.
Qiu Q, Li C, Zhao X, Yang M, Ding S, Liang H CNS Neurosci Ther. 2024; 30(11):e70127.
PMID: 39592913 PMC: 11598744. DOI: 10.1111/cns.70127.
Efficiency of IL-6 in Early Prognosis and Follow-Up in Critically Ill Patients with Septic Shock.
Gamarra-Morales Y, Molina-Lopez J, Santiago-Ruiz F, Herrera-Quintana L, Vazquez-Lorente H, Gascon-Luna F Diseases. 2024; 12(11).
PMID: 39589972 PMC: 11592789. DOI: 10.3390/diseases12110298.
Zhou X, Dai N, Yu D, Niu T, Wang S J Endocrinol Invest. 2024; .
PMID: 39565520 DOI: 10.1007/s40618-024-02506-z.